PURPOSE: The aim of the study was to investigate the in vitro antiinfective effect of piperacillin-tazobactam (PIP-TZB) combinations on Escherichia coli in simulations of free concentration time profiles of both drugs, similar to those obtained in human tissue after i.v. bolus administrations. METHODS: An in vitro dilution model was used to expose E. coli ATCC 35218 (beta-lactamase producer) to various piperacillin-tazobactam concentration profiles obtained after i.v. bolus multiple dose, using different dose ratio combinations (1:4, 1:8, 1:16) and dosing regimens, ranging from once-a-day to 4 times a day. The antimicrobial effect was evaluated by determination of the number of bacteria over time. The concentration of PIP in the model was determined by HPLC. RESULTS: A modified Emax model was used to describe the pharmacodynamic effect. The model was linked with the piperacillin concentrations determined experimentally to provide a pharmacokinetic-pharmacodynamic (PK-PD) model. The EC50 for piperacillin alone averaged 5.66 +/- 0.29 micrograms/ml. The EC50 for all doses of piperacillin combined with 0.5 g of tazobactam were dose-dependent and averaged 1.70 +/- 0.56, 3.95 +/- 1.02, and 6.14 +/- 1.24 micrograms/ml for PIP 2, 4, and 8 g, respectively. By increasing the dose of TZB in combination with a fixed dose of PIP, a decreased EC50 was observed. CONCLUSIONS: The PK-PD model allowed a detailed evaluation of the dosing regimens investigated. The results suggested that for these combinations, 3 times a day administration is as effective as 4 times a day. Pharmacodynamic activity of the combinations can be prolonged by sufficiently high inhibitor concentrations.
PURPOSE: The aim of the study was to investigate the in vitro antiinfective effect of piperacillin-tazobactam (PIP-TZB) combinations on Escherichia coli in simulations of free concentration time profiles of both drugs, similar to those obtained in human tissue after i.v. bolus administrations. METHODS: An in vitro dilution model was used to expose E. coli ATCC 35218 (beta-lactamase producer) to various piperacillin-tazobactam concentration profiles obtained after i.v. bolus multiple dose, using different dose ratio combinations (1:4, 1:8, 1:16) and dosing regimens, ranging from once-a-day to 4 times a day. The antimicrobial effect was evaluated by determination of the number of bacteria over time. The concentration of PIP in the model was determined by HPLC. RESULTS: A modified Emax model was used to describe the pharmacodynamic effect. The model was linked with the piperacillin concentrations determined experimentally to provide a pharmacokinetic-pharmacodynamic (PK-PD) model. The EC50 for piperacillin alone averaged 5.66 +/- 0.29 micrograms/ml. The EC50 for all doses of piperacillin combined with 0.5 g of tazobactam were dose-dependent and averaged 1.70 +/- 0.56, 3.95 +/- 1.02, and 6.14 +/- 1.24 micrograms/ml for PIP 2, 4, and 8 g, respectively. By increasing the dose of TZB in combination with a fixed dose of PIP, a decreased EC50 was observed. CONCLUSIONS: The PK-PD model allowed a detailed evaluation of the dosing regimens investigated. The results suggested that for these combinations, 3 times a day administration is as effective as 4 times a day. Pharmacodynamic activity of the combinations can be prolonged by sufficiently high inhibitor concentrations.
Authors: M Brunner; U Hollenstein; S Delacher; D Jäger; R Schmid; E Lackner; A Georgopoulos; H G Eichler; M Müller Journal: Antimicrob Agents Chemother Date: 1999-05 Impact factor: 5.191
Authors: Roland R Regoes; Camilla Wiuff; Renata M Zappala; Kim N Garner; Fernando Baquero; Bruce R Levin Journal: Antimicrob Agents Chemother Date: 2004-10 Impact factor: 5.191
Authors: M Frossard; C Joukhadar; B M Erovic; P Dittrich; P E Mrass; M Van Houte; H Burgmann; A Georgopoulos; M Müller Journal: Antimicrob Agents Chemother Date: 2000-10 Impact factor: 5.191
Authors: Yoriko Harigaya; Jürgen B Bulitta; Alan Forrest; George Sakoulas; Alan J Lesse; Joseph M Mylotte; Brian T Tsuji Journal: Antimicrob Agents Chemother Date: 2009-07-13 Impact factor: 5.191
Authors: Nageshwar R Budha; Robin B Lee; Julian G Hurdle; Richard E Lee; Bernd Meibohm Journal: Tuberculosis (Edinb) Date: 2009-09-11 Impact factor: 3.131
Authors: John J Veillette; S Alexander Winans; Victoria K Maskiewicz; James Truong; Ronald N Jones; Steven C Forland Journal: Eur J Drug Metab Pharmacokinet Date: 2021-03-20 Impact factor: 2.569